Akari Therapeutics PLC (AKTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.54M
Last updated: Nov 17, 2026 at 10:59 AM ET
Akari Therapeutics PLC (AKTX) Stock Forecast
Analysts expect Akari Therapeutics (AKTX) to earn -$9.05 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$8.65.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$9.05
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$8.65
- EPS consensus
- Fiscal year ending Dec 31, 2028
- -$6.27
- EPS consensus
- Next report
- Mar 29, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$9.05 | -$9.05 to -$9.05 | 1 |
| Dec 31, 2027 | -$8.65 | -$8.65 to -$8.65 | 1 |
| Dec 31, 2028 | -$6.27 | -$6.27 to -$6.27 | 2 |
Quarterly Estimates
The EPS consensus falls from -$0.94 for the quarter ending Dec 31, 2026 to -$2.09 for the quarter ending Mar 31, 2027.
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.94 | N/A | 4 |
| Mar 31, 2027 | -$2.09 | -$2.09 to -$2.09 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
Frequently Asked Questions About AKTX
What is the AKTX stock forecast?
Consensus analyst estimates put Akari Therapeutics's EPS at -$9.05 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from AKTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$9.05, with estimates from -$9.05 to -$9.05 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$8.65, with estimates from -$8.65 to -$8.65 from 1 analyst.
How many analysts cover AKTX?
1 analyst estimates EPS for Akari Therapeutics for the fiscal year ending Dec 31, 2026.
AKTX pages: Overview, Earnings, Forecast, Financials, Competitors